From July 5 to 7, 2024, the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA) was grandly held in Guangzhou. On the 6th, Professor Xiaojie Bian from Fudan University Shanghai Cancer Center shared the latest drug development progress for metastatic castration-resistant prostate cancer (mCRPC) from the 2024 ASCO annual meeting in the urologic tumor session, showcasing the new radioligand drug JNJ-6420 and the PROTAC AR-766.

As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let's innovate together for a future where cancer treatment knows no borders.

From July 5-7, 2024, the 2024 Chinese Clinical Oncology Annual Progress Seminar (BOC) and Beast of ASCO® 2024 China were grandly held in Guangzhou. On the 6th, a special session on urinary system tumors convened, gathering significant progress from ASCO. In the field of kidney cancer treatment, besides international advancements, China has made significant strides in first-line and second-line treatments involving immunotherapy combinations and HIF-2α inhibitors, showcasing China’s cutting-edge scientific strength on the international stage. At this conference, "Oncology Frontier" invited Professor Jun Guo from Peking University Cancer Hospital to provide an overview of the current status and prospects of advanced kidney cancer treatment. Additionally, Professor Pei Dong from Sun Yat-sen University Cancer Center was interviewed to discuss the unmet clinical needs and cutting-edge developments in kidney cancer treatment domestically and internationally, and to grasp the trends in combination therapy for kidney cancer.

In recent years, the accurate detection of HER2 (human epidermal growth factor receptor 2) expression in breast cancer has become crucial for guiding personalized treatment strategies. However, the heterogeneity of HER2 expression, including spatial and temporal heterogeneity, poses challenges for clinical decision-making. In this article, Professor Songqing Ye from Fujian Provincial Hospital delves into the impact of tumor HER2 expression heterogeneity and how to select appropriate samples (primary or metastatic lesions) for testing to utilize novel ADC drugs effectively, aiming to provide more precise guidance for personalized treatment of breast cancer patients.

For premenopausal patients with HR+/HER2- metastatic breast cancer (mBC), treatment choices are complex due to physiological characteristics, tumor properties, and treatment tolerance. Many patients receive chemotherapy early due to endocrine resistance and concerns about rapid tumor progression, with capecitabine being a commonly used regimen. At the 2024 ASCO conference, the latest updated survival results from the Young-PEARL randomized phase II study were presented. The study evaluated the safety and clinical anti-tumor efficacy of palbociclib combined with GnRHa and exemestane versus capecitabine in premenopausal HR+/HER2- mBC patients. Oncology Frontier interviewed the primary investigator, Professor Yeon Hee Park from Samsung Medical Center in Seoul, Korea, to discuss the study's background, methods, main results, and clinical significance. This comparative study provides significant insights into endocrine therapy for HR+/HER2- advanced breast cancer, offering a valuable alternative to traditional chemotherapy.

In the field of breast cancer treatment, gene testing for early-stage breast cancer has become a vital component of precision medicine. By deeply analyzing the genetic expression profiles of patients, we can more accurately predict disease progression and develop more personalized adjuvant treatment strategies. However, how is gene testing currently applied in clinical practice, and what challenges remain? Oncology Frontier invited Professor Qiang Zhang from Liaoning Cancer Hospital & Institute to discuss the FLEX study presented at the 2024 ASCO conference.

Editor's Note: From July 5-7, 2024, the 2024 Chinese Clinical Oncology Annual Progress Seminar (BOC) and Beast of ASCO® 2024 China were grandly held in Guangzhou. On the 6th, a…

On June 27, 2024, Nature Communications published the results of a phase 1 clinical trial conducted by Professor Binghe Xu, an academician of the Chinese Academy of Engineering, and his joint team. The study focuses on a novel HER2 antibody-drug conjugate (ADC), FS-1502, which offers a potential new treatment option for HER2-positive breast cancer patients.

The mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) was held from June 28-30, 2024, in Shanghai. Young talents from across the country gathered to share experiences and discuss the future. Several experts shared their clinical and translational research experiences during the conference. Clinical research derived from practice is crucial for enhancing medical innovation, bridging the gap between basic research and clinical practice, and improving the medical research funding landscape. Oncology Frontier invited Professor Wenxing Qin from Fudan University Shanghai Cancer Center to share his experiences in clinical and translational research, balancing research, life, and clinical work, and choosing research directions.